Xcyte Therapies Inc
Business Identifier: Autologous T cells for cancer
Public Profile:
A struggling Xcyte Therapies Inc. reached two separate agreements that result in the closure of the company's facilities in Seattle in 2006-07. Xcyte sold its intellectual property and accumulated clinical data relating to its T-cell expansion technology to Carlsbad, Calif.-based Invitrogen Inc. (NASDAQ: IVGN) for $5 million in cash and possible future payments. Xcyte had stopped all clinical trials earlier this year, though six trials had been conducted on Xcellerated T-Cells as a cancer treatment. Separately, Xcyte agreed to merge with Cyclacel Group PLC, a private biotech company based in Scotland. The merged company will be called Cyclacel Pharmaceuticals Inc. and be based in Short Hills, N.J. All facilities in Seattle closed and the research facilities located in the United Kingdom. Cyclacel shareholders owned 80% of the merged company, with former Xcyte shareholders holding the balance. The newly merged entity buildt upon Cyclacel's cell cycle biology, which has resulted in a portfolio of three orally available, mechanism-targeted drugs that modulate the cancer cell cycle. Those drug candidates are all in early to midstage clinical trials. Xcyte's decline has been coming for some time. In March 2006, Xcyte Therapies Inc. had been acquired by Cyclacel Group plc. in a reverse merger transaction. Xcyte Therapies, Inc., a development stage biotechnology company, developing therapeutic products that enhance the body’s natural immune responses to treat cancer, infectious diseases, and other medical conditions associated with weakened immune systems. Its therapeutic products consist of activated, patient-specific T cells, using the company’s patented and proprietary Xcellerate Technology. The company uses blood collected from the patient to generate activated T cells, called Xcellerated T Cells. The Xcellerate Technology activates and expands the patient’s T cells outside of the body. Xcyte completed a Phase I clinical trial of its proprietary Xcellerate Technology in advanced kidney cancer. The company is also conducting Phase I/II clinical trials in multiple myeloma and chronic lymphocytic leukemia. In addition to cancer and HIV, Xcellerated T Cells can be used to treat patients with other illnesses, including infectious diseases, such as hepatitis.

 Synopsis: Awardee Business Condition
Year Founded IP Holdings
Employee Range VC funded?
Revenue Range Private/Public
 Most Recent SBIR Projects
Year Phase Agency Dollars Project Title
Autologous T Cell Therapy for CLL